Time Trends of Etiologies of Blindness in Israel 2009-2020:Have Methods to Decrease Leading Causes of Blindness Been Exhausted?


Journal

American journal of ophthalmology
ISSN: 1879-1891
Titre abrégé: Am J Ophthalmol
Pays: United States
ID NLM: 0370500

Informations de publication

Date de publication:
08 2022
Historique:
received: 30 12 2021
revised: 02 03 2022
accepted: 03 03 2022
pubmed: 16 3 2022
medline: 27 7 2022
entrez: 15 3 2022
Statut: ppublish

Résumé

To perform a nationwide analysis of trends in the incidence of etiologies for legal blindness in Israel during 2009-2020, and to compare the results with those of the previous decade. Descriptive, retrospective population-based trend study. Data were retrieved from the Israeli National Registry of the Blind during 2009-2020. Data obtained included demographics, years of registration, and causes. Primary and secondary outcomes were the incidence of new certified blindness cases and its comparison with that of the previous decade, respectively. The age-standardized incidence rate of blindness in Israel decreased from 15.76 per 100,000 residents in 2009 to 11.83 in 2020, a 24.9% drop. The mean annual decline was evident until 2013 (P < .001, 6.15%), but subsequently flattened (P = .71, 0.42%). Age-related macular degeneration (AMD), glaucoma, optic atrophy, and cataract decreased until 2014, and reached a plateau that was maintained until the end of the study period. Diabetic retinopathy (DR) incidence rates diminished throughout the decade (P < .001, 9.2%), with attenuation of the rate of decline after 2014. The impact of efforts to reduce the incidence of preventable causes of blindness may have nearly reached saturation for most of the leading causes of blindness in Israel, namely, AMD, glaucoma and cataract. The incidence of DR has been maintained; however, attenuation has been observed. New modalities to detect and treat these causes may have to emerge before a resurgence of improvement can occur.

Identifiants

pubmed: 35288071
pii: S0002-9394(22)00104-0
doi: 10.1016/j.ajo.2022.03.010
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

149-158

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Asaf Israeli (A)

The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel; (A.I., E.M.).

Hani Peer (H)

Service for the Blind, Deaf and Assistive Technology. Ministry of Welfare and Social Affairs, Jerusalem, Israel (H.P., I.G., Y.F.).

Ilana Gleitman (I)

Service for the Blind, Deaf and Assistive Technology. Ministry of Welfare and Social Affairs, Jerusalem, Israel (H.P., I.G., Y.F.).

Yishay Falick (Y)

Service for the Blind, Deaf and Assistive Technology. Ministry of Welfare and Social Affairs, Jerusalem, Israel (H.P., I.G., Y.F.); Misgav Ladach Hospital, Jerusalem, Israel (Y.F.).

Eedy Mezer (E)

The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel; (A.I., E.M.); Department of Ophthalmology, Rambam Health Care Campus, Haifa, Israel; (E.M.). Electronic address: emezer@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH